XK
ALXN

Xact Kapitalforvaltning’s Alexion Pharmaceuticals ALXN Stock Holding History

Xact Kapitalforvaltning’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$4.2M Sell
46,750
-2,574
-5% -$253K 0.09% 195
2019
Q4 		$5.33M Buy
49,324
+1,611
+3% +$172K 0.09% 205
2019
Q3 		$4.67M Buy
47,713
+4,288
+10% +$483K 0.09% 210
2019
Q2 		$5.69M Buy
43,425
+2,185
+5% +$282K 0.12% 169
2019
Q1 		$5.58M Buy
41,240
+4,507
+12% +$560K 0.13% 160
2018
Q4 		$3.58M Sell
36,733
-8,532
-19% -$1.01M 0.09% 206
2018
Q3 		$6.29M Sell
45,265
-1,605
-3% -$201K 0.13% 150
2018
Q2 		$5.82M Sell
46,870
-1,882
-4% -$220K 0.12% 163
2018
Q1 		$5.43M Buy
48,752
+2,920
+6% +$349K 0.12% 171
2017
Q4 		$5.48M Buy
45,832
+3,789
+9% +$461K 0.13% 171
2017
Q3 		$5.9M Buy
42,043
+537
+1% +$73K 0.17% 136
2017
Q2 		$5.05M Buy
41,506
+5,076
+14% +$591K 0.15% 154
2017
Q1 		$4.42M Buy
36,430
+2,434
+7% +$314K 0.14% 175
2016
Q4 		$4.16M Buy
33,996
+1,817
+6% +$222K 0.15% 161
2016
Q3 		$3.94M Buy
+32,179
New +$4.14M 0.14% 163

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Xact Kapitalforvaltning's ALXN Position: Q1 2020 in Review

Xact Kapitalforvaltning reduced its Alexion Pharmaceuticals (ALXN) stake by 5.2% in Q1 2020, selling an estimated $253K and leaving 46,750 shares worth $4.2M. The position accounts for 0.09% of the portfolio, ranked #195.

Xact Kapitalforvaltning first reported a position in ALXN in Q3 2016 and has held it in 15 quarters since. The position peaked at $6.29M in Q3 2018. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Xact Kapitalforvaltning held 46,750 shares of Alexion Pharmaceuticals worth $4.2M as of Q1 2020.
  • Xact Kapitalforvaltning sold 2,574 Alexion Pharmaceuticals shares in Q1 2020, an estimated $253K.
  • Alexion Pharmaceuticals made up 0.09% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #195 holding.
  • Xact Kapitalforvaltning first reported a position in Alexion Pharmaceuticals in Q3 2016 and has held it in 15 quarters since.
  • Xact Kapitalforvaltning's Alexion Pharmaceuticals position peaked at $6.29M in Q3 2018.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.